Salma Abbas1, Jillian E Raybould2, Sangeeta Sastry2, Oveimar de la Cruz2. 1. Division of Infectious Diseases, Virginia Commonwealth University, Richmond, Virginia, USA. Electronic address: salma.abbas@vcuhealth.org. 2. Division of Infectious Diseases, Virginia Commonwealth University, Richmond, Virginia, USA.
Abstract
OBJECTIVES: The aim of this review is to provide updated information on the clinical spectrum, treatment options, and infection prevention strategies for respiratory viral infections (RVIs) in both solid organ (SOT) and hematopoietic stem cell transplant (HSCT) patients. METHODS: The MEDLINE and PubMed databases were searched for literature regarding the aforementioned aspects of RVIs, with focus on respiratory syncytial virus, adenovirus, influenza virus, parainfluenza virus, human metapneumovirus, and rhinovirus. RESULTS: Compared to immunocompetent hosts, SOT and HSCT patients are much more likely to experience a prolonged duration of illness, prolonged shedding, and progression of upper respiratory tract disease to pneumonia when infected with respiratory viruses. Adenovirus and respiratory syncytial virus tend to have the highest mortality and risk for disseminated disease, but all the RVIs are associated with higher morbidity and mortality in these patients than in the general population. These viruses are spread via direct contact and aerosolized droplets, and nosocomial spread has been reported. CONCLUSIONS: RVIs are associated with high morbidity and mortality among SOT and HSCT recipients. Management options are currently limited or lack strong clinical evidence. As community and nosocomial spread has been reported for all reviewed RVIs, strict adherence to infection control measures is key to preventing outbreaks.
OBJECTIVES: The aim of this review is to provide updated information on the clinical spectrum, treatment options, and infection prevention strategies for respiratory viral infections (RVIs) in both solid organ (SOT) and hematopoietic stem cell transplant (HSCT) patients. METHODS: The MEDLINE and PubMed databases were searched for literature regarding the aforementioned aspects of RVIs, with focus on respiratory syncytial virus, adenovirus, influenza virus, parainfluenza virus, human metapneumovirus, and rhinovirus. RESULTS: Compared to immunocompetent hosts, SOT and HSCT patients are much more likely to experience a prolonged duration of illness, prolonged shedding, and progression of upper respiratory tract disease to pneumonia when infected with respiratory viruses. Adenovirus and respiratory syncytial virus tend to have the highest mortality and risk for disseminated disease, but all the RVIs are associated with higher morbidity and mortality in these patients than in the general population. These viruses are spread via direct contact and aerosolized droplets, and nosocomial spread has been reported. CONCLUSIONS: RVIs are associated with high morbidity and mortality among SOT and HSCT recipients. Management options are currently limited or lack strong clinical evidence. As community and nosocomial spread has been reported for all reviewed RVIs, strict adherence to infection control measures is key to preventing outbreaks.
Authors: Sherry G Mansour; Divyanshu Malhotra; Michael Simonov; Yu Yamamoto; Tanima Arora; Labeebah Subair; Jameel Alausa; Dennis G Moledina; Jason H Greenberg; Francis Perry Wilson; Ethan P Marin Journal: Kidney360 Date: 2021-01-12
Authors: Karoly Toth; Islam T M Hussein; Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; Jessica Eagar; Scott H James; Mark N Prichard; William S M Wold; Terry L Bowlin Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Deborah A Theodore; William G Greendyke; Benjamin Miko; Susan Whittier; Daniel A Green; Sherif Shoucri; Elizabeth C Verna; Jason Zucker; Magdalena E Sobieszczyk; Justin G Aaron; Brian E Scully; Lisa Saiman; Marcus Pereira; E Yoko Furuya Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385
Authors: Xunyan Ye; Wanderson Cabral de Rezende; Obinna Patrick Iwuchukwu; Vasanthi Avadhanula; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra Journal: Vaccines (Basel) Date: 2020-04-21
Authors: Claas Baier; Christin Linderkamp; Andreas Beilken; Felicitas Thol; Michael Heuser; Ella Ebadi; Tina Ganzenmueller; Albert Heim; Franz-Christoph Bange Journal: GMS Hyg Infect Control Date: 2018-09-24
Authors: Kevin J Downes; Lara A Danziger-Isakov; Melissa K Cousino; Michael Green; Marian G Michaels; William J Muller; Rachel C Orscheln; Tanvi S Sharma; Victoria A Statler; Rachel L Wattier; Monica I Ardura Journal: J Pediatric Infect Dis Soc Date: 2020-11-10 Impact factor: 3.164